688163 赛伦生物
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)3.1934.6914.0613.5138.610
总资产报酬率 ROA (%)3.0454.5483.9403.3798.181
投入资产回报率 ROIC (%)3.1594.6514.0083.4468.387

边际利润分析
销售毛利率 (%)78.28178.12178.05775.70983.770
营业利润率 (%)38.91532.87726.67024.18442.855
息税前利润/营业总收入 (%)38.41032.04125.08422.67240.964
净利润/营业总收入 (%)34.21126.39422.72320.39236.849

收益指标分析
经营活动净收益/利润总额(%)97.09986.739101.80188.00678.660
价值变动净收益/利润总额(%)14.55216.48610.22322.75621.667
营业外收支净额/利润总额(%)-1.492-0.469-2.806-1.252-0.843

偿债能力分析
流动比率 (X)16.07924.71546.70037.97937.104
速动比率 (X)15.35023.54944.49536.18835.075
资产负债率 (%)5.3973.8502.1903.7783.845
带息债务/全部投入资本 (%)0.4230.3510.2270.3330.294
股东权益/带息债务 (%)23,389.08628,159.14143,849.60829,465.78033,387.045
股东权益/负债合计 (%)1,752.8092,497.3914,465.3532,547.0122,500.496
利息保障倍数 (X)577.305-46.896-29.206-18.689-26.735

营运能力分析
应收账款周转天数 (天)96.95266.73254.77528.69717.841
存货周转天数 (天)333.422361.884370.449386.922660.221